**FOI Ref: 6184**

**Category(ies): Clinical - Drugs**

**Subject: Usage of biologic and biosimilar products within Rheumatology**

**Date Received: 13/01/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Analysing the usage of biologic and biosimilar products within Rheumatology.  It would be really helpful if you could answer the following two questions: | |
| Q1. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:   * Abatacept [Orencia] * Adalimumab [Humira] * Adalimumab Biosimilars * Apremilast [Otezla] * Baricitinib [Olumiant] * Certolizumab [Cimzia] * Etanercept [Enbrel] * Etanercept Biosimilars * Filgotinib [Jyseleca] * Golimumab [Simponi] * Guselkumab [Tremfya] * Infliximab [Remicade] * Infliximab Biosimilars * Ixekizumab [Taltz] * Risankizumab [Skyrizi] * Rituximab [MabThera] * Rituximab Biosimilars * Sarilumab [Kevzara] * Secukinumab [Cosentyx] * Tocilizumab [Ro Actemra] * Tofacitinib [Xeljanz] * Upadacitinib [Rinvoq] * Ustekinumab [Stelara] | * 30 * 0 * 113 * 0 * 35 * 0 * 6 * 238 * 0 * 9 * 0 * 0 * 15 * 0 * 0 * 0 * 9 * 0 * 16 * 39 * 3 * 1 * 3 |
| Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs.   * Adalimumab [Humira] * Adalimumab Biosimilars * Certolizumab [Cimzia] * Etanercept [Enbrel] * Etanercept Biosimilars * Golimumab [Simponi] * Infliximab [Remicade] * Infliximab Biosimilars * Ixekizumab [Taltz] * Secukinumab [Cosentyx] * Upadacitinib [Rinvoq] | No patients currently meet the criteria of been treated with a medicine in the list where the primary diagnosis was either M479 (Spondyloarthrosis) or M45 (Ankylosing Spondylitis).  As December coding may not be complete yet this figure could change for December. |